| Assay Prediction |
Pathology |
Clinical Features |
| Tissue of Origin |
Veridex |
Histology |
IHC |
Age/Sex |
Sites of Metastasis |
Intra-abdominal Location (Y/N) |
Response to Treatment |
Survival (mo) |
| Colorectal |
Colon |
Adenocarcinoma |
CK20+, CK7-, TTF1-, CEA- |
73/F |
Pleura, left adrenal |
Y |
SD |
23 |
| Colorectal |
Other |
Adenocarcinoma |
None |
64/F |
Liver, omentum, peritoneum, pancreas |
Y |
UE |
1 |
| Colorectal |
Pancreas |
Adenocarcinoma |
CK7+, CK20-, CA125-, TTF1-, CEA- |
66/F |
Liver |
Y |
UE |
4 |
| Colorectal |
NSCLC |
PD adenocarcinoma |
CK+, CK20+, PLAP-, PSA/PSAP-, melanin A- |
71/M |
Abdomen, Soft tissue |
Y |
SD |
21 |
| Pancreas |
Colon |
Adenocarcinoma |
None |
44/F |
Liver, abdominal wall, peritoneum |
Y |
UE |
1 |
| Kidney |
Colon |
PD carcinoma |
CK+, calretinin+, vimentin+, chromogranin-, CD15-, CD10-, AFP-, CEA- |
64/M |
Liver, peritoneum |
Y |
SD |
6 |
| NSCLC |
Colon |
Squamous |
None |
59/M |
Lymph nodes, internal jugular vein mass |
N |
PD |
7 |
| |
|
|
|
|
|
|
|
|
| Ovary |
Ovary |
PD carcinoma |
CK7+, ER+, PR+, GCDFP15-, HER2- |
69/F |
Lung, liver, lymph nodes, pelvis, abdomen |
Y |
PR |
57 |
| Ovary |
Ovary |
PD carcinoma |
AE1/AE3+, CK7+, EMA+, CK5/6+, calretinin+, pan keratin+, CEA-, CK20-, LeuM1-, thyroglobulin-, ER-, PR-, Her2/neu-, HMB45-, S100-,chromogranin-, synaptophysin-, NSE- |
45/F |
Lung, bone, pelvis, lymph nodes, mediastinum |
Y |
SD |
6 |
| Ovary |
Other |
Adenocarcinoma |
CK7+, CD15+, CEA+, calretinin-, CK20-, GCDFP15-, S100-, TTF1- |
70/F |
Lung |
N |
PR |
19 |
| Ovary |
Other |
PD adenocarcinoma |
None |
48/F |
Lung, liver, mediastinum |
Y |
SD |
18 |
| Ovary |
NSCLC |
PD adenocarcinoma |
CK+, CK7+, CEA+, ER-, PR-, HER2-, CK20-, HMB45-, S100- |
51/F |
Lung, liver |
Y |
PD |
5 |
| Sarcoma |
Ovary |
PD carcinoma |
vimentin+, NSE+, CD117+, synaptophysin+, S100-, HMB45-, LCA-, chromogranin-, actin-, desmin-, pan CK-, EMA- |
40/F |
Lung, liver, pelvis |
Y |
PD |
9 |
|
